$0.89
4.92% today
Nasdaq, Apr 03, 06:51 pm CET
ISIN
US6409791000
Symbol
NMRA
Sector
Industry

Neumora Therapeutics Stock price

$0.94
-0.46 33.07% 1M
-13.03 93.27% 6M
-9.66 91.13% YTD
-12.83 93.17% 1Y
-16.06 94.47% 3Y
-16.06 94.47% 5Y
-16.06 94.47% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.03 2.97%
ISIN
US6409791000
Symbol
NMRA
Sector
Industry

Key metrics

Market capitalization $152.33m
Enterprise Value $-154.61m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.85
P/B ratio (TTM) P/B ratio 0.53
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-263.46m
Free Cash Flow (TTM) Free Cash Flow $-182.94m
Cash position $308.79m
EPS (TTM) EPS $-1.53
P/E forward negative
Short interest 15.02%
Show more

Is Neumora Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Neumora Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Neumora Therapeutics forecast:

3x Buy
33%
5x Hold
56%
1x Sell
11%

Analyst Opinions

9 Analysts have issued a Neumora Therapeutics forecast:

Buy
33%
Hold
56%
Sell
11%

Financial data from Neumora Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.63 0.63
80% 80%
-
-0.63 -0.63
80% 80%
-
- Selling and Administrative Expenses 61 61
56% 56%
-
- Research and Development Expense 201 201
41% 41%
-
-263 -263
42% 42%
-
- Depreciation and Amortization 0.63 0.63
80% 80%
-
EBIT (Operating Income) EBIT -263 -263
40% 40%
-
Net Profit -244 -244
3% 3%
-

In millions USD.

Don't miss a Thing! We will send you all news about Neumora Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Neumora Therapeutics Stock News

Neutral
GlobeNewsWire
14 minutes ago
NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Neumora Therapeutics, Inc. (NASDAQ: NMRA).
Neutral
PRNewsWire
about 8 hours ago
NEW YORK , April 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Neumora Therapeutics, Inc. (NASDAQ: NMRA). Shareholders who purchased shares of NMRA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Neutral
GlobeNewsWire
3 days ago
Investors can contact the law firm at no cost to learn more about recovering their losses
More Neumora Therapeutics News

Company Profile

Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. It offers a precision medicine approach for brain diseases through the integration of data science and neuroscience. The firm focuses on advancing medicines for therapeutically relevant targets implicated in CNS diseases, targeting novel mechanisms of action with best-in-class pharmacology. The company was founded by Paul L. Berns, Carol Suh and Mike Poole in November 2019 and is headquartered in Watertown, MA.

Head office United States
CEO Paul Berns
Employees 110
Founded 2019
Website www.neumoratx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today